	porpolally.	•	
It is made available und	der a <mark>CC-B</mark> Y	4.0 International	license.

1	Inhibitory control and its modification in spider phobia –
2	study protocol for an antisaccade training trial
3	Short title: Assessing and training fear inhibition in spider phobia via eye-movements.
4	
5	Anne Sophie Hildebrand ^a
6	Contact: Anne.Hildebrand@uni-siegen.de
7	Department of Psychology, Clinical Psychology and Psychotherapy of the University of Siegen,
8	57072, Siegen, Germany.
9	
10	Fabian Breuer ^a
11	Contact: breuerfa@uni-muenster.de
12	Institute for Translational Psychiatry of the University of Münster, 48149, Münster, Germany.
13	
14	Elisabeth Johanna Leehr
15	Contact: leehr@uni-muenster.de
16	Institute for Translational Psychiatry of the University of Münster, 48149, Münster, Germany.
17	
18	Johannes B. Finke
19	Contact: Johannes.Finke@uni-siegen.de
20	Department of Psychology, Clinical Psychology and Psychotherapy of the University of Siegen,
21	57072, Siegen, Germany.
22	
23	Leandra Bucher
24	Contact: Leandra.Bucher@uni-siegen.de

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 Department of Psychology, Clinical Psychology and Psychotherapy of the University of Siegen,

- 26 57072, Siegen, Germany.
- 27
- 28 Tim Klucken
- 29 Contact: Tim.Klucken@uni-siegen.de
- 30 Department of Psychology, Clinical Psychology and Psychotherapy of the University of Siegen,
- 31 57072, Siegen, Germany.
- 32
- 33 Udo Dannlowski
- 34 Contact: udo.dannlowski@uni-muenster.de
- 35 Institute for Translational Psychiatry of the University of Münster, 48149, Münster, Germany.

36

- 37 Kati Roesmann^b
- 38 Contact: kati.roesmann@uni-osnabrueck.de
- 39 Institute of Psychology of the University of Osnabrück, 49076 Osnabrück, Germany.
- 40
- 41 ^a Shared first authorship
- 42 ^b Corresponding author

43 Abstract

Objectives: Inhibitory control deficits are considered a key pathogenic factor in anxiety 44 disorders. To assess inhibitory control, the antisaccade task is a well-established measure, 45 assessing antisaccade performance via latencies and error rates. The present study follows three 46 aims: (1) to investigate inhibitory control via antisaccade latencies and errors in an antisaccade 47 task, and their associations with multiple measures of fear in patients with spider phobia (SP) 48 versus healthy controls (HC), (2) to investigate the modifiability of antisaccade performance 49 via a fear-specific antisaccade training in patients with SP and HC, and (3) to explore 50 associations between putative changes in antisaccade performance in SPs and diverse measures 51 52 of fear following the training.

Methods: Towards aim 1, we assess antisaccade latencies (primary outcome) and error rates 53 (secondary outcome) in an emotional antisaccade task. Further, the baseline assessment 54 includes assessments of psychophysiological, behavioral, and psychometric indices of fear in 55 patients with SP and HCs. To address aim 2, we compare effects of a fear-specific antisaccade 56 training with effects of a prosaccade training as a control condition. The primary and secondary 57 outcomes are reassessed at a post-1-assessment in both SPs and HCs. Aim 3 employs a cross-58 over design and is piloted in patients with SP, only. Towards this aim, primary and secondary 59 60 outcomes, as well as psychophysiological, behavioral, and psychometric measures of fear are 61 reassessed at a post-2-assessment after the second training block.

62 **Conclusion:** This study aims to better understand inhibitory control processes and their 63 modifiability in spider phobia. If successful, antisaccade training may assist in the treatment of 64 specific phobia by directly targeting the putative underlying inhibitory control deficits. This 65 study has been preregistered with ISRCTN (ID: ISRCTN12918583) on 28th February 2022.

66 Keywords

Antisaccade task, specific phobia, inhibitory control, skin conductance response, startleresponse

69 Background

Specific phobia constitutes the most prevalent anxiety disorder with a prevalence 70 ranging from 1.5% to 14.4% in adults [1]. Specific phobia is characterized by excessive fear of 71 a specific object (e.g. spiders) or a specific situation [2]. Real or expected confrontation with 72 the fear-evoking stimulus elicits a direct fear reaction, thus prompting habitual avoidance of 73 this stimulus. While specific phobia can be treated effectively [2], studies show that about one-74 third of patients do not benefit from common first-line treatments [3, 4]. A better understanding 75 of the neurocognitive underpinnings of specific phobia as a model for anxiety disorders may 76 pave the way for developing mechanism-informed targeted interventions that could add to the 77 existing methods of treatment and address the problem of non-response to treatment. 78

Anxiety can be characterized by a fast initial shift in attention, in favor of threatening 79 stimuli [5]. The Attentional-Control Theory distinguishes two systems that are involved in 80 attentional control: a goal-driven top-down system and a stimulus-driven bottom-up system [6]. 81 The presence of a fear-evoking stimulus is assumed to disrupt the balance of these systems in 82 83 favor of bottom-up processing, causing a shift of attention towards the fear-evoking stimulus. 84 From an evolutionary perspective, this is a highly adaptive mechanism preparing organisms for fast reactions towards (potential) threats [7]. Yet, if too sensitive, this mechanism may 85 contribute to pathological anxiety, which is - amongst other aspects (e.g., avoidance, increased 86 psychophysiological responses [8]) - characterized by an inability to adequately inhibit bottom-87 up-driven perceptual processes. 88

A well-established experimental task to assess inhibitory control is the antisaccade task [9]. In the antisaccade task, participants are instructed to look in the opposite direction of a peripherally presented visual stimulus. Indices of reduced inhibitory control are prolonged latencies of correct antisaccades and increased error rates (gaze at the visual stimulus, instead of the opposite direction). While the latency of correct antisaccades constitutes a measure of

inhibitory control efficiency, the error rate reflects the effectiveness of inhibitory control 94 95 performance [10]. Antisaccades have been used in a variety of different psychiatric populations to assess inhibitory control. Perhaps most prominently, the antisaccade task has been applied in 96 the research of psychotic and schizophrenic disorders [9], however it has also been used to 97 study inhibitory control in obsessive-compulsive disorder [11], post-traumatic stress disorder 98 [12], binge-eating disorder [13], attentional-deficit-hyperactivity disorder [14], and alcohol use 99 disorder [15]. Additionally, research has identified reduced inhibitory control efficiency, 100 indexed by prolonged latencies of correct antisaccades, in a multitude of highly anxious, yet 101 subclinical participants [16, 17]. Reduced inhibitory control at high levels of (dispositional) 102 103 anxiety is further reported in a meta-analysis investigating the association between inhibitory control and anxiety in a multitude of different tasks [18]. In line with this, it is considered a risk 104 and maintaining factor of pathological anxiety [19]. Surprisingly, there are no studies 105 106 investigating inhibitory control via antisaccade performance in patients with specific phobia. Thus, the profile of probable inhibitory control deficits in patients with specific phobia and its 107 association with other indices of fear, like avoidance behavior and psychophysiological 108 responses, remains elusive. Furthermore, it is unclear, whether patients with specific phobia 109 show impaired inhibitory control only in response to phobia-relevant stimuli or if they exhibit 110 111 a general deficit in inhibitory control.

In previous studies, antisaccade training improved antisaccade performance in nonclinical and clinical samples [20, 21]. In a sample of patients with binge eating disorder, antisaccade training improved not only antisaccade performance in response to disorder specific stimuli (i.e., high-caloric food), but was also associated with a significant decrease of binge eating incidents. However, no changes could be found in psychometric measures associated with binge eating (e.g., food craving [21]). To date, there are no studies investigating the trainability of antisaccade performance in specific phobia.

To further elucidate the role of inhibitory control performance in specific phobia, the 119 120 present study investigates antisaccade performance in patients with spider phobia (SP) compared to healthy controls (HC). As the literature on (dispositional) anxiety and inhibitory 121 control mainly indicates inhibitory control deficits with regard to efficiency rather than 122 effectiveness, antisaccade latency serves as the primary outcome. Antisaccade error rate (as a 123 marker of inhibitory control effectiveness) is investigated as a secondary outcome. Our study 124 125 follows three main aims: First, patients with spider phobia (as a model anxiety disorder) will be investigated via the antisaccade task regarding potential inhibitory control deficits and their 126 associations to stimulus category (phobia-related versus neutral), psychophysiological (heart 127 128 rate, skin conductance, startle-response), behavioral and psychometric measures of fear (aim 1). This aim employs a proof-of-concept mixed factorial design with the between subject factors 129 group (SPs vs. HCs) and the within-subject factor stimulus material (phobia-related vs. neutral). 130 131 Second, the modifiability of inhibitory control through a fear-specific antisaccade training will be piloted (aim 2). This aim employs an exploratory randomized controlled parallel group 132 design with two training conditions (antisaccade training vs. control) that will be realized in 133 SPs and HCs. Changes in antisaccade performance from baseline to post-1-assessment, and 134 their dependence on stimulus material will assessed. Third, putative changes in inhibitory 135 136 control performance following the training will be investigated regarding associations to changes in psychophysiological, behavioral, and psychometric measures of fear in SPs, 137 therefore exploring possible therapeutic utility (aim 3). This aim employs an exploratory cross-138 139 over design in SPs only, i.e. patients will switch training conditions after the post-1-assessment, and will be assessed regarding antisaccade performance, psychophysiological (heart rate, skin 140 conductance, startle-response), behavioral and psychometric measures of fear at post-2-141 assessment. 142

143 Methods

144 Participants

Participants with a specific phobia of the animal subtype (spiders) and HCs are recruited 145 at the University of Siegen and from the general population. Interested participants are invited 146 to a short telephone screening (~ 10 minutes) and then enrolled in a more extensive clinical 147 interview (~ 1 hour) via telephone to assess further eligibility, conducted by trained research 148 assistants. SPs have to fulfill the criteria of specific phobia according to the Diagnostic and 149 Statistical Manual of Mental Disorders-IV (SCID-I, Section F [22], while HCs must not fulfill 150 the criteria of spider phobia and not exceed a value of 19 points in the Spider Phobia 151 Questionnaire (SPQ) [23]. Inclusion criteria for both groups are an age between 18 and 65 years, 152 normal or corrected to normal vision, as well as normal hearing. Exclusion criteria are any 153 psychiatric condition (except spider phobia, as well as a mild to moderate depressive episode 154 in the past SPs) assessed via the Mini-International Neuropsychiatric Interview (MINI) [24]. 155 Furthermore, any history of neurological disorders, current intake of Benzodiazepines or 156 Barbiturates, astigmatism, hearing disorders, subjective auditory hypersensitivity, regular 157 nicotine consumption (> 5 cigarettes/day) or known allergy to bites of insects and arachnids 158 lead to exclusion. 159

160 Sample size

Based on two studies using the antisaccade task in clinical samples, we calculated two a-priori power analyses using G*Power 3.1 [25] for ANOVAs (Analyses of Variance) to detect large effect sizes (Cohen's f = .40, $\alpha = .05$, power = .85) in our primary outcome (i.e. antisaccade latencies) at baseline (aim 1) [12] and for the training effect (aim 2) [21]. Results indicated a required total sample size of 59 participants (30 per group).

166 **Procedure**

167 *Overall procedure*

After an initial telephone screening, eligible participants are invited to provide written informed consent and participate in a clinical interview via telephone. If they fulfill eligibility criteria, they are invited to a laboratory appointment at the University of Siegen and asked to fill in an online battery of questionnaires, including the SPQ [23], beforehand via LimeSurvey 3.28.18 [26]. A schedule of enrollment, intervention and assessment can be found in Figure 1.

173

174 Figure 1

175 Schedule of Enrollment, Intervention, and Assessment

176 [insert figure 1 about here]

Note. Assessment schedule, including all outcome measures. An X in the corresponding box 177 indicates that assessment takes place at a certain time point. BAT: Behavioral Avoidance Test. 178 179 MINI: Mini International Neuropsychiatric Interview [24]. SPQ: Spider Phobia Questionnaire [23]. BIS: Behavioral Inhibition System [27]. BAS: Behavioral Approach System [27]. NEO-180 FFI: NEO Five-Factor Inventory [28]. STAI: State-Trait-Anxiety-Inventory [29]. FEAS: 181 Questionnaire on Disgust and Fear of Spiders [30]. ABI: inventory of coping with anxiety [31]. 182 CERQ: Cognitive Emotion Regulation Questionnaire [32]. PANAS: Positive and Negative 183 Affect Schedule [33]. UI-18: Intolerance of Uncertainty [34]. ASI-3: Anxiety Sensitivity Index 184 [35]. NISS: Need Inventory of Sensation Seeking [36]. RSES: Rosenberg Self-Esteem Scale 185 [37]. ANPS: Affective Neuroscience Personality Scales [38]. SEE: Scales for experiencing 186 187 emotions [39]. MWT-B: Multiple-Choice Vocabulary Intelligence Test [40]. FEE: Disgust Responsiveness [41]. 188

189

The laboratory appointment begins with a baseline assessment, including a behavioral
avoidance test (BAT), a free-viewing task, and the antisaccade task (all of which are described

below). This part of the study corresponds to aim 1 (see *background* and Figure 2). Then, 192 193 participants will complete the antisaccade training or the control condition (prosaccade training), according to a randomization scheme. After training, the antisaccade task and the 194 BAT will be repeated (post-1-assessment), and the study ends for the HCs. This part of the 195 study corresponds to aim 2 (see *background* and Figure 2). The SPs will then complete a second 196 training. Here, participants switch training conditions. After the second training, the antisaccade 197 task, the free-viewing task, the BAT, and the SPQ will be repeated (post-2-assessment). This 198 part of the study corresponds to aim 3 (see *background* and Figure 2). 199

200

201 **Figure 2**

202 [insert figure 2 about here]

203 The Consort Flow Diagram

Note. BAT: Behavioral avoidance test. HC: Healthy control participants. n: Number of participants. SP: Participants with spider phobia. SPQ: Spider phobia questionnaire. Key assessments to address aim 1 are shaded in green (baseline-assessment). Additionally, the intervention (antisaccade and prosaccade training) and the post-1-assessment are relevant for aim 2 (i.e., areas shaded in green and blue). In addition to assessments targeting aim 1 and 2, a second intervention and the post-2-assessments is relevant for aim 3 (i.e., areas shaded in green, blue and yellow). Note: Aim 3 refers to participants with spider phobia, only.

211

212 Laboratory assessments

213 Antisaccade Task

In the antisaccade task, ten stimuli, created and used by Kolassa and colleagues in previous studies [42], are presented. Stimulus material comprises five phobia-related pictures (black schematic pictures of spiders) and five neutral pictures (black schematic pictures of

flowers), as depicted in Figure 3, to assess the stimulus-dependency of predicted differences ininhibitory control functions.

219 Figure 3

220 [insert figure 3 about here]

221 Overview of Tasks and Intervention

Note. A: Antisaccade task, employs stimuli from [42]. B: Free-viewing task, uses phobiarelated stimuli from GAPED [43]. C: Antisaccade training, uses additional phobia-related
stimuli from GAPED. Arrows show the instructed viewing direction of the participants. D:
Prosaccade training, uses neutral stimuli from GAPED. Arrows show the instructed viewing
direction of the participants. ITI: Inter-Trial-Interval. s: Seconds.

227

The antisaccade task is conducted at baseline, post-1- and post-2-assessment. For each assessment, participants are placed in a darkened room. Eye movements are recorded via Eye-Link 1000 plus (SR Research Ltd., Canada) at a sampling rate of 1000 Hz. For each trial, a black fixation dot $(0.25^{\circ} \times 0.25^{\circ})$ is presented on a white screen, with 84 cm distance to the participant, for a period of 1.5 - 3.5 seconds. After the fixation period, the dot vanishes, and the visual stimulus is immediately presented (so-called step-paradigm). The visual stimulus (3° x 2.25°) is randomly presented at 12° to the left or right of the visual field for one second.

235 Phobia-related and neutral stimuli are presented equally often in a randomized order. At baseline, the task includes five blocks as proposed by Antoniades and colleagues [44]: three 236 antisaccade blocks (each including 40 antisaccades, i.e. 20 antisaccades to phobia-related and 237 20 antisaccades to neutral stimuli, each stimuli will be shown 4 times), as well as two 238 prosaccade blocks (each including 60 prosaccades, i.e. 30 prosaccades to phobia-related and 30 239 240 prosaccades to neutral stimuli, each stimuli will be shown 6 times), one preceding and one following the antisaccade blocks. Antisaccade tasks at post-1- and post-2-assessment include 241 only three blocks of antisaccades (each including 40 antisaccades), as prosaccades are already 242

assessed at baseline, expenses for participants should be reduced and outcomes are only related 243

to antisaccade performance. Each block is followed by a one-minute break. 244

- Assessment of antisaccade performance will be relevant for aims 1 3 of the study. 245
- 246

Free-Viewing Task and Valence and Arousal Rating

In the free-viewing task, 24 pictures of the Geneva Affective Picture Database (GAPED) 247 [43] are presented. The selected stimulus material comprises eight neutral pictures (inanimate 248 249 objects), eight generally aversive but phobia-unrelated pictures (animal mistreatment), and eight phobia-related pictures (naturalistic spiders), respectively. Pictures are presented in two 250 blocks of trials, each block depicting all of the 24 pictures in a randomized order. Via ratings 251 provided by the authors of the database [43], negative pictures and pictures of spiders were 252 matched regarding valence (negative: M = 21.35, SD = 8.78; spider: M = 20.46, SD = 7.77, 253 t(15) = 1.00, p = .83) and arousal (negative: M = 66.30, SD = 5.18; spider: M = 66.99, SD = 5.18254 255 6.41, t(15) = 1.02, p = .84), while neutral pictures had higher valence (M = 50.54, SD = 1.65) and lower arousal ratings (M = 21.77, SD = 6.01). Pictures are presented for six seconds each, 256 257 followed by a twelve-second inter-trial-interval, as depicted in Figure 3.

While the pictures are presented, psychophysiological measures are assessed. To assess 258 participants' startle response, an acoustic stimulus (white noise, 50 ms, 105 dB(A), 259 instantaneous rise time) is presented via headphones. This stimulus is presented 18 times during 260 visual stimulus presentation for each block, that is six times per visual stimulus category, in a 261 randomized order. The startle-eliciting stimulus occurs randomly between 4 and 5.5 seconds 262 after visual stimulus onset. During inter-trial intervals, startle responses are elicited 6 times per 263 block in a randomized order between 7.5 and 9.5 seconds after inter-trial-interval onset. Before 264 each block, the startle-eliciting stimulus is presented 6 (first block) or 3 times (second block), 265 respectively, to ensure initial habituation. Startle magnitude is measured by activity of the 266 musculus orbicularis oculi (unilateral) via electromyography (EMG), utilizing a Biopac MP160 267 system (Biopac Systems, Inc., USA) with H124SG electrodes (Kendall). Design of startle 268

assessment closely follows established methods [45]. Heart rate will be derived from continuously recorded electrocardiogram (ECG) utilizing a Biopac MP160 system with EL503 electrodes (Biopac). To assess skin conductance responses, electrodermal activity [46, 47] is measured utilizing a Biopac MP160 system with EL507 electrodes (Biopac) at the thenar/hypothenar of the non-dominant hand.

Psychophysiological measures are assessed in the free-viewing task at baseline and post2-assessment and will be relevant to address aims 1 and 3 of the study.

Directly after the free-viewing task, each picture is presented again, and participants are asked to rate each picture in terms of valence and arousal on a visual analog scale. Pictures and the sequence of the valence and arousal ratings are randomized between participants. Ratings are used to describe stimulus-characteristics based on the study sample.

280

Behavioral Avoidance Test (BAT)

Avoidance behavior is assessed by an in vivo BAT. Behavioral avoidance is indexed by the final distance (in cm) between the participant and a spider (brachypelma auratum). For a detailed description, also see [48]. BAT is conducted at baseline, post-1- and post-2-assessment and will be relevant to address aims 1 and 3 of the study.

285 Intervention

286

Experimental Condition (Antisaccade Training)

The intervention in this trial will constitute an antisaccade training. Participants must 287 288 look at the center of a screen. As depicted in Figure 3, stimuli will be presented for one second left or right in the periphery field of vision with a visual angle of 12°, after a fixation period of 289 1 - 3.5 seconds, based on recommendations by Antoniades and colleagues [44]. Participants are 290 instructed to look at the mirrored position on the screen. Stimuli will constitute ten (additional) 291 292 spider stimuli from the GAPED [43], which are shown in random order. We opted for phobiarelated stimuli because the training of inhibitory control would be expected to be maximal in 293 this condition. The training includes two blocks with 80 antisaccades each, separated by a pause 294

of one minute. Adherence to interventions will be improved by carefully instructing participants
before each training block. Implementation of the described training (including the control
condition described below) will be relevant to address aims 2 and 3 of the study.

298

Control Condition (Prosaccade Training)

To examine the effect of antisaccade training on antisaccade performance, we will compare the effects of the antisaccade training with the effects of a prosaccade training on antisaccade performance. The prosaccade training was employed to control for potential fatigue effects caused by voluntary eye movements in general rather than antisaccades specifically.

In the control condition, as depicted in Figure 3, participants are instructed to look at stimuli that appear left or right in the periphery field of vision for one second after a fixation period of 1 - 3.5 seconds. Ten neutral stimuli from the *GAPED* [43] are used. In the control condition, we employ neutral stimuli rather than the phobia-related stimuli employed in the antisaccade training to prevent potentially beneficial effects of perceptual exposure on antisaccade performance. The training includes two blocks with 80 prosaccades each, separated by a pause of 60 seconds.

310 Outcome

The primary outcome of this study is correct antisaccade latency, measured at baseline, post-1- and post-2-assessment in the antisaccade task. The secondary outcome is antisaccade error rate, also measured at baseline, post-1- and post-2-assessment in an antisaccade task.

Psychophysiological measures include startle response, heart rate, and skin conductance level, measured at baseline and post-2-assessment in a free-viewing task. As a behavioral assessment, the final distance in the behavioral avoidance test (BAT) will be conducted at baseline, post-1- and post-2-assessment. For psychometric assessment, the SPQ will be conducted at baseline and post-2-assessment.

Exploratory analyses will be conducted to pilot a fear-specific antisaccade training. Therefore, potential changes in antisaccade performance will be associated with changes in psychophysiological, behavioral, and psychometric measures of fear.

To characterize the sample, we will additionally obtain a range of self-report measures, described in Figure 1. All self-assessment questionnaires will be given out in the German version.

- 325 Analysis
- 326 Preprocessing

Eve Tracking: To detect saccadic eve movements, conservative thresholds are used. 327 Saccades are defined as eye movements with a velocity $> 35^{\circ}/\text{sec}$, an acceleration $> 9500^{\circ}/\text{sec}^2$ 328 and an amplitude $> 3^{\circ}$. For the trial to be classified as valid, onset latency of the first saccadic 329 eve movement after stimulus onset must be greater than 70 ms. Starting coordinates of the eve 330 movement must fall within a square of 5° x 5° around the fixation stimulus. Additionally, blinks 331 must be absent. Trials with no recorded eye movements after stimulus onset are also classified 332 as invalid. A correct antisaccade (secondary outcome) is defined as a valid saccade in the 333 opposite direction of the peripheral visual stimulus. Antisaccade latency (primary outcome) is 334 defined as the time difference between stimulus onset and initiation of the correct antisaccade. 335 336 Participants will be excluded from analysis if > 50% of maximal possible trials are invalid.

Psychophysiological data: ECG data is pre-processed using the PhysioData Toolbox
(Version 0.6.3; [49]. The signal is filtered using a bandpass filter with a low cut-off at 1 Hz and
a high cut-off at 50 Hz. From the ECG signal, R-peaks are retrieved, which serve to calculate
heart rate measures. The ECG signal will be visually inspected for artifacts, as well as erroneous
or missed R-peaks. Missed R-peaks will be added manually, erroneous R-peaks will be deleted.
Trials with artifacts in the ECG signal will be discarded.

343 Skin conductance data is pre-processed using the PhysioData Toolbox. The raw signal 344 is filtered and resampled to a 20 Hz time-vector spanning the length of the filtered signal, using

spline interpolation. By first applying a moving minimum filter, followed by smoothing the result applying a Gaussian kernel, the tonic component is calculated. The phasic component is calculated by applying a 1st order high pass Butterworth filter of 0.5 Hz. The signal will be visually inspected for artifacts. Trials with artifacts in the SCL signal will be discarded.

The raw EMG signal is filtered using a band-pass filter ranging from 10 to 500 Hz, as 349 well as rectified and smoothed, using a low-pass resistor-capacitor filter, utilizing a time 350 351 constant of 10 ms. A C++-based software tool will be used to identify peak responses in the rectified and integrated EMG signal. Additionally, the signal will be visually inspected for 352 artifacts (e.g., preceding blinks immediately before the startle probe), as well as erroneously 353 354 detected response peaks. Trials with artifacts in the EMG signal will be discarded, erroneously detected response peaks will be corrected manually. Startle response amplitude is defined as 355 the difference between EMG peak and baseline amplitude in a 200 ms response window. 356

357 Statistical Analyses

In the following, planned analyses will be described in brief. Further details on statistical analyses for <u>aim 1</u> and <u>aim 2</u>, can be found in the detailed statistical analyses protocols for each aim. For further details on aim 3, a statistical analyses protocols will be preregistered with Current Controlled Trials (ID: ISRCTN12918583).

Corresponding to aim 1 of the study, baseline differences in antisaccade performance 362 between participants with SP and HCs will be investigated using general linear modeling with 363 antisaccade latency and antisaccade error as outcome respectively. Diagnosis will be entered as 364 a between-subject-factor, stimulus category as a within-subject factor, resulting in a 2x2 design. 365 366 To investigate associations between multimodal measures of fear (psychophysiological responses, BAT and SPQ scores) and antisaccade performance in SPs, multiple regression 367 368 analyses will be conducted with the primary and secondary outcome as dependent variables, 369 respectively. If relevant demographic or psychometric measures differ between groups, these measures will be entered as covariates (for statistical analysis plan see ISRCTN12918583). 370

Corresponding to aim 2 of the study, general linear modelling will be conducted with diagnosis and intervention (antisaccade training vs. prosaccade training) as between-subject factors, as well as time and stimulus category as within-subject factors, resulting in a 2x2x2 design, including antisaccade latency and error rate as outcomes. Again, potential confounds showing group differences will be entered as covariates (for <u>statistical analysis plan</u> see ISRCTN12918583).

Corresponding to aim 3 of the study, exploratory analyses will be conducted in SPs, 377 associating changes in antisaccade performance (antisaccade latency and error rate, pre vs. post-378 2) with changes in physiological responses to fear-specific stimuli, avoidance behavior, and 379 self-reported fear of spiders (baseline vs. post-2). Additionally, antisaccade latencies and error-380 381 rates will be investigated via general linear modelling with intervention (antisaccade training first vs. prosaccade training first) as between-subject factors, as well as time (baseline, post-1, 382 post-2) and stimulus category as within-subject factors, resulting in a 2x2x3 design. BAT scores 383 will be investigated via general linear modelling with intervention (antisaccade training first vs. 384 prosaccade training first) as between-subject factors, and time (baseline, post-1, post-2) as 385 386 within-subject factor.

For all analyses significance levels will be set to p = .05.

388 **Discussion**

The present study is designed to compare the antisaccade performance of SPs to a HC group and to examine the putative potential of an antisaccade training with phobia-related stimuli to increase inhibitory control in specific phobia. It also aims to explore associations between antisaccade performance and multimodal psychophysiological, behavioral, and psychometric measures of fear.

Focusing on the comparison of SPs and HCs (aim 1), a decreased antisaccade performance in SPs would yield evidence for reduced inhibitory control functions in SPs. This

finding would extend previous findings, which have yielded evidence for associations between 396 397 antisaccade performance and subclinical anxiety levels [16, 17], to clinically anxious individuals. Thereby, such findings would provide further evidence for a key role of inhibitory 398 control processes in the pathogenesis and maintenance of specific phobia. Such evidence from 399 400 the study of antisaccade performance would complement previous evidence from the field of fear conditioning, which has suggested deficient inhibitory learning processes and reduced 401 402 inhibition of fear responses to safe stimuli in patients with pathological anxiety [50] and nonresponders to exposure therapy in spider phobia [51]. As spider phobia is used as a model 403 disorder for anxiety disorders more broadly, results could also serve as foundation for research 404 405 on a wider range of anxiety disorders.

To estimate the clinical relevance of putative deficits in antisaccade performance (i.e., 406 inhibitory control), it seems pivotal to shed light to its link with symptoms of fear. We therefore 407 408 investigate relationships between antisaccade performance and multimodal measures of fear (e.g., psychophysiological fear responses, avoidance behavior as assessed via the BAT, and 409 self-reported symptoms as assessed via the SPQ). The finding of significant associations could 410 broaden our knowledge on the mechanistic basis of specific aspects of the fear response and 411 412 form the basis for future research on a potential (causal) role of inhibitory control on fear-413 associated symptoms.

If a lower inhibitory control is found in patients with pathological anxiety, an 414 antisaccade training could increase antisaccade performance as seen in previous studies 415 416 investigating patients with other disorders [20, 21]. Aim 2 of this study targets this hypothesis. A positive result would suggest that an antisaccade training does increase inhibitory processes, 417 which may in turn be a factor related to treatment outcomes in specific phobia (for review, see 418 [52]. If this is the case, the generalizability of improved antisaccade performance to clinically 419 relevant measures of fear and anxiety would be of importance. According to aim 3 of this study, 420 421 we therefore investigate whether changes in antisaccade performance generalize to other

422 measures of fear. Positive results regarding aim 2 and potentially also aim 3 would point 423 towards the potential of the antisaccade training as a mechanism-informed targeted intervention 424 for anxiety disorders [53]. As such, it might yield add-on effects to existing treatments and 425 increase treatment response.

To conclude, findings of this study on patients with spider phobia (as a model for anxiety disorders more broadly) can strengthen our understanding of the mechanistic underpinnings of anxiety disorders and potentially pave the way for new targeted interventions.

429

430 Abbreviations

ABI: an inventory of coping with anxiety; ANOVA: Analysis of Variance. ANPS: Affective 431 Neuroscience Personality Scales; ASI-3: Anxiety Sensitivity Index; BAS: Behavioral Approach 432 433 System; BAT: Behavioral Avoidance Test; BIS: Behavioral Inhibition System; CERQ: the Cognitive Emotion Regulation Questionnaire; dB: decibel; ECG: electrocardiography. EMG: 434 electromyography. FEAS: Questionnaire on Disgust and Fear of Spiders; FEE: Disgust 435 436 Responsiveness; GAPED: Geneva Affective Picture Database; HC: Healthy control participants; Hz: hertz; ITI: Inter-Trial-Interval; m: meters. MINI: Mini International 437 Neuropsychiatric Interview; ms: milliseconds. MWT-B: Multiple-Choice Vocabulary 438 439 Intelligence Test; n: number of participants; NISS: Need Inventory of Sensation Seeking; NEO-FFI: NEO Five-Factor Inventory; PANAS: Positive and Negative Affect Schedule; RSES: 440 Rosenberg Self-Esteem Scale; s: seconds; SCID-I: Structured clinical interview for the 441 Diagnostic and Statistical Manual of Mental Disorders-IV; SCL: Skin Conductance Level. 442 SEE: Scales for experiencing emotions; SP: Patients with spider phobia; SPQ: Spider Phobia 443 444 Questionnaire; STAI: State-Trait-Anxiety-Inventory; UI-18: Intolerance of Uncertainty Scale

445

446

447 **Declarations**

448 **Trial status**

The trial (protocol version 1) was registered with Current Controlled Trials (ID:
ISRCTN12918583) on 28th February 2022. The recruitment process began at the 1st of March

451 2022 and will finish on the 31^{st} of December 2023.

452 Acknowledgements

- 453 The study is funded by the DGPs (German Society for Psychology: Biological Psychology and
- 454 Neuropsychology) and Movisens (Peer-Mentoring-Program, awarded to FB and KR), and the
- 455 Innovative Medizinische Forschung (IMF) of the medical faculty of the University of Münster
- 456 (awarded to EJL, grant numbers: ME121805; LE121904). AH is supported by the German
- 457 Research Foundation (Research Training Group 2493/1: 398510439).
- 458 Study materials were provided by Iris-Tatjana Kolassa and colleges and the Geneva Affective459 Picture Database (GAPED).
- 460 The study is sponsored by the University of Siegen (Adolf-Reichwein-Straße 2, 57072 Siegen,
- 461 Germany; Contact: +49 271 740-4106, <u>tim.klucken@psychologie.uni-siegen.de</u>).
- 462 The funders of the study are not involved in the collection, analysis, and interpretation of data.
- 463 The sponsor of the study is involved in designing the study, and analysis and interpretation of464 data.
- 465

466 **Conflict of Interests**

- 467 The authors declare that they have no competing interests.
- 468 Authors' contributions

ASH, FB, EJL, JBF, LB, TK, UD, and KR designed the study. ASH, FB, and KR drafted the
manuscript. ASH and FB are responsible for data collection and monitoring. All authors read
and approved the final manuscript. The trial is carried out by the involved researchers and

472 research assistants. While the involved researchers meet once every other month to check on

473 data collection and management and on demand, all researchers responsible for data collection

474 meet once a week to report on data collection and possible adverse events.

475 In case of important protocol modifications, all relevant parties (e.g., the respective researchers

476 and trial registries) will be informed.

477 Availability of data and materials

478 The responsible researchers and research assistants will have access to the final dataset. Data

and statistical code will be provided upon reasonable request.

480 Ethics approval and consent to participate

481 The study protocol was approved by the local Ethics Committee of the University of Siegen (07/2021), Germany (reference number: ER 39 2021). The study was designed in accordance 482 with the Declaration of Helsinki, Good Clinical Practice guidelines, and the SPIRIT reporting 483 guidelines. During the run of the study, ethical, legal, and social aspects are anticipated and 484 addressed. Participants provide written informed consent to the experimental procedure before 485 inclusion in the study. Informed consent is obtained by research assistants conducting the 486 interviews for eligibility. Participation is entirely voluntary, and participants have the right to 487 withdraw their consent at any time. Participant information is pseudonymized and stored on a 488 489 secure database and can only be accessed by the involved researchers and research assistants.

490 Randomization and Blinding

491 The randomization scheme was implemented utilizing block randomization. Participants are492 randomized via sequential numbers provided in a separate document.

493 Though participants are not especially informed about their allocation to a certain condition,

they might have been aware of the condition. A blinding of investigators is not possible.

495 **Consent for publication**

496 Not applicable.

497 The study protocol or parts of it have not been published elsewhere.

498 **References**

- 1. Eaton WW, Bienvenu OJ, Miloyan B. Specific phobias. The Lancet Psychiatry.
- 500 2018;5:678–86. doi:10.1016/S2215-0366(18)30169-X.
- 2. Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel EM. The diagnosis of and treatment
- 502 recommendations for anxiety disorders. Deutsches Ärzteblatt International.
- 503 2014;111:473. doi:10.3238/arztebl.2014.0473.
- 3. Loerinc AG, Meuret AE, Twohig MP, Rosenfield D, Bluett EJ, Craske MG. Response
- rates for CBT for anxiety disorders: Need for standardized criteria. Clin Psychol Rev.
- 506 2015;42:72–82. doi:10.1016/j.cpr.2015.08.004.
- Fernandez E, Salem D, Swift JK, Ramtahal N. Meta-analysis of dropout from cognitive
 behavioral therapy: Magnitude, timing, and moderators. Journal of Consulting and
 Clinical Psychology. 2015;83:1108. doi:10.1037/ccp0000044.
- 5. Mobini S, Grant A. Clinical implications of attentional bias in anxiety disorders: An
 integrative literature review. Psychotherapy (Chic). 2007;44:450–62. doi:10.1037/00333204.44.4.450.
- 513 6. Eysenck MW, Derakshan N, Santos R, Calvo MG. Anxiety and cognitive performance:
- attentional control theory. Emotion. 2007;7:336–53. doi:10.1037/1528-3542.7.2.336.
- 515 7. Roesmann K, Lueken U. Timeo–ergo sum: Ein evolutionsbiologischer Blick auf
- 516 Angststörungen. PiD-Psychotherapie im Dialog. 2022;23:36–9. doi:10.1055/a-1686-1514.
- 517 8. Löw A, Weymar M, Hamm AO. When threat is near, get out of here: Dynamics of
- 518 defensive behavior during freezing and active avoidance. Psychological science.
- 519 2015;26:1706–16. doi:10.1177/0956797615597332.

9.	Hutton SB, Ettinger U. The antisaccade task as a research tool in psychopathology: a
	critical review. Psychophysiology. 2006;43:302-13. doi:10.1111/j.1469-
	8986.2006.00403.x.
10.	Ansari TL, Derakshan N. Anxiety impairs inhibitory control but not volitional action
	control. Cognition and emotion. 2010;24:241-54. doi:10.1080/02699930903381531.
11.	Bey K, Lennertz L, Grützmann R, Heinzel S, Kaufmann C, Klawohn J, et al. Impaired
	Antisaccades in Obsessive-Compulsive Disorder: Evidence From Meta-Analysis and a
	Large Empirical Study. Front Psychiatry. 2018;9:284. doi:10.3389/fpsyt.2018.00284.
12.	Reinhard M, Allen N, Wong LM, Schwartz BL. Neuropsychological measurement of
	inhibitory control in posttraumatic stress disorder: An exploratory antisaccade paradigm.
	Journal of Clinical and Experimental Neuropsychology. 2017;39:1002-12.
	doi:10.1080/13803395.2017.1301389.
13.	Leehr EJ, Schag K, Dresler T, Grosse-Wentrup M, Hautzinger M, Fallgatter AJ, et al.
	Food specific inhibitory control under negative mood in binge-eating disorder: Evidence
	from a multimethod approach. Int J Eat Disord. 2018;51:112–23. doi:10.1002/eat.22818.
14.	Chamorro Y, Betz LT, Philipsen A, Kambeitz J, Ettinger U. The Eyes Have It: A Meta-
	analysis of Oculomotor Inhibition in Attention-Deficit/Hyperactivity Disorder. Biol
	Psychiatry Cogn Neurosci Neuroimaging 2021. doi:10.1016/j.bpsc.2021.05.004.
15.	Schag K, Rauch-Schmidt M, Wernz F, Zipfel S, Batra A, Giel KE. Transdiagnostic
	investigation of impulsivity in alcohol use disorder and binge eating disorder with eye-
	tracking methodology—A pilot study. Front Psychiatry. 2019;10:724.
	 9. 10. 11. 12. 13. 14. 15.

16. Basanovic J, Notebaert L, Clarke PJF, MacLeod C, Jawinski P, Chen NTM. Inhibitory

542 attentional control in anxiety: Manipulating cognitive load in an antisaccade task. PLoS

543 One. 2018;13:e0205720. doi:10.1371/journal.pone.0205720.

- 544 17. Derakshan N, Ansari TL, Hansard M, Shoker L, Eysenck MW. Anxiety, inhibition,
- 545 efficiency, and effectiveness. An investigation using antisaccade task. Exp Psychol.

546 2009;56:48–55. doi:10.1027/1618-3169.56.1.48.

- 547 18. Shi R, Sharpe L, Abbott M. A meta-analysis of the relationship between anxiety and
- ttentional control. Clin Psychol Rev. 2019;72:101754. doi:10.1016/j.cpr.2019.101754.
- 549 19. van Bockstaele B, Verschuere B, Tibboel H, Houwer J de, Crombez G, Koster EHW. A

review of current evidence for the causal impact of attentional bias on fear and anxiety.

551 Psychological bulletin. 2014;140:682. doi:10.1037/a0034834.

- 552 20. Jamadar SD, Johnson BP, Clough M, Egan GF, Fielding J. Behavioral and neural
- 553 plasticity of ocular motor control: changes in performance and fMRI activity following

antisaccade training. Frontiers in human neuroscience. 2015;9:653. doi:10.1007/s00221-

555 004-2105-9.

- 556 21. Giel KE, Speer E, Schag K, Leehr EJ, Zipfel S. Effects of a food-specific inhibition
- training in individuals with binge eating disorder—Findings from a randomized
- 558 controlled proof-of-concept study. Eating and Weight Disorders-Studies on Anorexia,

559 Bulimia and Obesity. 2017;22:345–51. doi:10.1007/s40519-017-0371-3.

- 560 22. Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the Structured Clinical
- 561 Interview for DSM-IV Axis I disorders (SCID I) and Axis II disorders (SCID II). Clinical
- 562 psychology & psychotherapy. 2011;18:75–9. doi:10.1002/cpp.693.

- 563 23. Olatunji BO, Woods CM, Jong PJ de, Teachman BA, Sawchuk CN, David B.
- 564 Development and initial validation of an abbreviated Spider Phobia Questionnaire using
- item response theory. Behavior Therapy. 2009;40:114–30.
- 566 doi:10.1016/j.beth.2008.04.002.
- 567 24. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. The Mini
- 568 International Neuropsychiatric Interview (MINI). A short diagnostic structured interview:
- reliability and validity according to the CIDI. European psychiatry. 1997;12:224–31.
- 570 doi:10.1016/S0924-9338(97)83296-8.
- 571 25. Faul F, Erdfelder E, Lang A-G, Buchner A. G* Power 3: A flexible statistical power
- analysis program for the social, behavioral, and biomedical sciences. Behavior research
 methods. 2007;39:175–91. doi:10.3758/BF03193146.
- 574 26. Limesurvey GmbH. LimeSurvey: An Open Source survey tool. Hamburg: Limesurvey
 575 GmbH; 2022.
- 576 27. Strobel A, Beauducel A, Debener S, Brocke B. Eine deutschsprachige version des
- 577 BIS/BAS-Fragebogens von carver und white. Zeitschrift für Differentielle und
- 578 diagnostische Psychologie 2001. doi:10.1024/0170-1789.22.3.216.
- 579 28. Körner A, Geyer M, Roth M, Drapeau M, Schmutzer G, Albani C, et al.
- 580 Persönlichkeitsdiagnostik mit dem NEO-Fünf-Faktoren-Inventar: Die 30-Item-
- 581 Kurzversion (NEO-FFI-30). [Personality assessment with the NEO-Five-Factor
- 582 Inventory: the 30-Item-Short-Version (NEO-FFI-30)]. Psychother Psychosom Med
- 583 Psychol. 2008;58:238–45. doi:10.1055/s-2007-986199.

- 584 29. Barnes LLB, Harp D, Jung WS. Reliability generalization of scores on the Spielberger
- state-trait anxiety inventory. Educational and psychological measurement. 2002;62:603–
- 586 18. doi:10.1177/0013164402062004005.
- 30. Schaller E, Gerdes A, Alpers GW, editors. Angst ungleich ekel: der fragebogen zu ekel
 und angst vor spinnen: Pabst Lengerich; 2006.
- 589 31. Krohne HW, Egloff B. Das Angstbewältigungs-Inventar (ABI). Frankfurt am Main 1999.
 590 doi:10.1007/978-3-642-18976-0 7.
- 591 32. Garnefski N, Kraaij V. The Cognitive Emotion Regulation Questionnaire. European
- Journal of Psychological Assessment. 2007;23:141–9. doi:10.1027/1015-5759.23.3.141.
- 33. Breyer B, Bluemke M. Deutsche Version der Positive and Negative Affect Schedule

594 PANAS (GESIS Panel). doi:10.6102/zis242.

- 595 34. Gerlach AL, Andor T, Patzelt J. Die Bedeutung von Unsicherheitsintoleranz für die
- 596 Generalisierte Angststörung Modellüberlegungen und Entwicklung einer deutschen
- 597 Version der Unsicherheitsintoleranz-Skala. Zeitschrift für Klinische Psychologie und
- 598 Psychotherapie. 2008;37:190–9. doi:10.1026/1616-3443.37.3.190.
- 599 35. Kemper CJ, Ziegler M, Taylor S. ASI-3-Angstsensitivitätsindex-3 2022.
- 600 doi:10.23668/psycharchives.4526.
- 36. Roth M, Hammelstein P. The Need Inventory of Sensation Seeking (NISS). European
- 502 Journal of Psychological Assessment. 2012;28:11–8. doi:10.1027/1015-5759/a000085.
- 603 37. Rosenberg M. Rosenberg self-esteem scale (RSE). Acceptance and commitment therapy.
- 604 Measures package. 1965;61:18.

- 38. Davis KL, Panksepp J, Normansell L. The affective neuroscience personality scales:
- Normative data and implications. Neuropsychoanalysis. 2003;5:57–69.
- 607 doi:10.1080/15294145.2003.10773410.
- 60839. Behr M, Becker M. SEE–Skalen zum Erleben von Emotionen (SEE). Zeitschrift für
- 609 Medizinische Psychologie. 2006:141.
- 40. Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest: MWT-B: Spitta; 1999.
- 41. Schienle A, Walter B, Stark R, Vaitl D. Ein fragebogen zur erfassung der
- 612 ekelempfindlichkeit (FEE). Zeitschrift für Klinische Psychologie und Psychotherapie.
- 613 2002;31:110–20. doi:10.1026/0084-5345.31.2.110.
- 42. Kolassa I-T, Musial F, Kolassa S, Miltner WHR. Event-related potentials when
- 615 identifying or color-naming threatening schematic stimuli in spider phobic and non-
- 616 phobic individuals. Bmc Psychiatry. 2006;6:1–12. doi:10.1186/1471-244X-6-38.
- 43. Dan-Glauser ES, Scherer KR. The Geneva affective picture database (GAPED): a new
- 618 730-picture database focusing on valence and normative significance. Behavior research
- 619 methods. 2011;43:468–77. doi:10.3758/s13428-011-0064-1.
- 620 44. Antoniades C, Ettinger U, Gaymard B, Gilchrist I, Kristjánsson A, Kennard C, et al. An
- 621 internationally standardised antisaccade protocol. Vision Research. 2013;84:1–5.
- 622 doi:10.1016/j.visres.2013.02.007.
- 45. Blumenthal TD, Cuthbert BN, Filion DL, Hackley S, Lipp OV, van Boxtel A. Committee
- 624 report: Guidelines for human startle eyeblink electromyographic studies.
- 625 Psychophysiology. 2005;42:1–15. doi:10.1111/j.1469-8986.2005.00271.x.

626	46. Kim KH	I, Bang SW	, Kim SR. Emot	ion recognition s	system using sh	ort-term monitoring	of
-----	------------	------------	----------------	-------------------	-----------------	---------------------	----

- 627 physiological signals. Medical and biological engineering and computing. 2004;42:419–
- 628 27. doi:10.1007/BF02344719.
- 47. Hamm AO, Cuthbert BN, Globisch J, Vaitl D. Fear and the startle reflex: Blink
- 630 modulation and autonomic response patterns in animal and mutilation fearful subjects.
- 631 Psychophysiology. 1997;34:97–107. doi:10.1111/j.1469-8986.1997.tb02420.x.
- 48. Schwarzmeier H, Leehr EJ, Böhnlein J, Seeger FR, Roesmann K, Gathmann B, et al.
- 633 Theranostic markers for personalized therapy of spider phobia: Methods of a bicentric
- external cross-validation machine learning approach. International journal of methods in
- 635 psychiatric research. 2020;29:e1812. doi:10.1002/mpr.1812.
- 49. Sjak-Shie EE. PhysioData Toolbox (Version 0.6.3); 2022.
- 50. Duits P, Cath DC, Lissek S, Hox JJ, Hamm AO, Engelhard IM, et al. Updated
- meta-analysis of classical fear conditioning in the anxiety disorders. Depression and
 anxiety. 2015;32:239–53.
- 51. Roesmann K, Leehr EJ, Böhnlein J, Steinberg C, Seeger F, Schwarzmeier H, et al.
- 641 Behavioral and magnetoencephalographic correlates of fear generalization are associated
- 642 with responses to later virtual reality exposure therapy in spider phobia. Biological
- 643 Psychiatry: Cognitive Neuroscience and Neuroimaging. 2022;7:221–30.
- 644 doi:10.1016/j.bpsc.2021.07.006.
- 52. Boehnlein J, Altegoer L, Muck NK, Roesmann K, Redlich R, Dannlowski U, Leehr EJ.
- Factors influencing the success of exposure therapy for specific phobia: A systematic
- review. Neuroscience & Biobehavioral Reviews. 2020;108:796–820.

- 53. Richter J, Pittig A, Hollandt M, Lueken U. Bridging the gaps between basic science and
- 649 cognitive-behavioral treatments for anxiety disorders in routine care: Current status and
- future demands. Zeitschrift für Psychologie. 2017;225:252.

651

	Enrollment	Online	Appointment				
medRxiv preprint doi: http preprint (which was no	s.//doi.org/10.1101/20	Battery 23.09.22.23295977 view) is the author	; this version poste /funder who has a	d September 25, 2 antednaer Rxiva I	023. The copyright	holder for this	Post-2
Participants	SP & Himade	avgilable under a	CCSP 40 Marnat	ongregeeHC	SP & HC	SP	SP
ENROLLMENT							
Screening for Eligibility	x						
Informed Consent	X						
Allocation	X						
Clinical Interview	X						
INTERVENTION				x		X	
FREE VIEWING							
Startle Response			X				Х
Heart rate			х				Х
Electrodermal Activity			X				Х
ANTISACCADE-							
TASK							
Latencies			х		х		Х
Error Rates			х		х		Х
BAT			Х		х		Х
SELF-REPORT							
MINI	Х						
SPQ	Х						Х
BIS/BAS		Х					
NEO-FFI		х					
STAI		Х					
FEAS		Х					
ABI		х					
CERQ		Х					
PANAS		х					
UI-18		Х					
ASI-3		х					
NISS		Х					
RSES		Х					
ANPS		Х					
SEE		х					
MWT-B							Х
FEE							Х

Figure 1



Figure 2

Α

В



Figure 3